Lotifazole (F 1686), a non-steroidal anti-inflammatory agent with an unusual pharmacological spectrum.
Lotifazole (F 1686) - 4-phenyl-2-(2',2',2-trichloroethoxycarboxamido) thiazole - has a range of anti-inflammatory activities in animals that differs from the activities of classic non-steroidal drugs. It reduces carrageenin-induced oedema in rats, UV-induced erythema in guinea pigs, and Arthus pleurisies in rats only at high doses. It does not affect Freund's-adjuvant polyarthritis, and it only slightly affects passive skin anaphylaxis in rats and anaphylactic shock in guinea pigs. Lotifazole does not greatly inhibit prostaglandin synthesis. However, at low doses and after various conditions of treatment, F 1686 reduces PPD- and Bordetella- pertussis-induced delayed-hypersensitivity pleurisy in guinea pigs and rats, respectively, and contact hypersensitivity reactions to picryl chloride and oxazolone in mice. Its action on the two models of delayed-hypersensitivity pleurisy is reflected in a decrease of the pleural exudate and of the number of mononuclear cells in the focus of inflammation. At active doses, Lotifazole does not cause changes in the differential leukocyte count in normal animals. It appears, furthermore, to be a T-lymphocyte stimulant.
D000707:Anaphylaxis / Q000188:drug therapy; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D001773:Blood Cells / Q000187:drug effects; D002219:Carbamates / Q000494:pharmacology*; D003877:Dermatitis, Contact / Q000188:drug therapy; D004890:Erythema / Q000188:drug therapy; D005260:Female; D006168:Guinea Pigs; D006968:Hypersensitivity, Delayed / Q000188:drug therapy; D008297:Male; D051379:Mice; D010323:Passive Cutaneous Anaphylaxis / Q000187:drug effects; D010998:Pleurisy / Q000188:drug therapy; D051381:Rats; D011919:Rats, Inbred Strains
D000893:Anti-Inflammatory Agents; D002219:Carbamates; C040605:lotifazole